Condensed Consolidated Balance Sheets (Unaudited) - USD ($) $ in Thousands	Sep. 30, 2025	Dec. 31, 2024
Current assets:
Cash and cash equivalents	$ 90,963	$ 174,960
Short-term marketable securities	757,241	657,371
Prepaid expenses and other current assets	34,394	32,105
Total current assets	882,598	864,436
Long-term marketable securities	24,703	359,373
Property and equipment, net	53,732	55,236
Finance lease right-of-use asset	49,447	47,533
Operating lease right-of-use asset	20,035	22,861
Other non-current assets	25,106	24,741
Total assets	1,055,621	1,374,180
Current liabilities:
Accounts payable	6,745	11,137
Accrued compensation	18,358	24,728
Accrued clinical and other research and development costs	23,355	22,822
Accrued manufacturing costs	5,002	12,779
Operating lease liability, current	9,164	8,308
Deferred research and development funding liability, current	22,580	14,129
Other accrued costs and current liabilities	4,942	8,305
Total current liabilities	90,146	102,208
Operating lease liability, less current portion	29,686	36,673
Finance lease liability, less current portion	5,554	5,615
Deferred research funding and development liability, less current portion	4,038	0
Total liabilities	129,424	144,496
Commitments and contingencies (Note 6)
Stockholders' equity:
Convertible preferred stock, $0.01 par value; 40,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 0 shares issued and outstanding as of September 30, 2025 and December 31, 2024	0	0
Common stock, $0.01 par value; 400,000,000 shares authorized as of September 30, 2025 and December 31, 2024; 146,625,722 shares and 144,220,986 shares issued and outstanding as of September 30, 2025 and December 31, 2024, respectively	1,793	1,768
Additional paid-in capital	2,846,278	2,764,880
Accumulated other comprehensive income	1,101	2,020
Accumulated deficit	(1,922,975)	(1,538,984)
Total stockholders' equity	926,197	1,229,684
Total liabilities and stockholders’ equity	$ 1,055,621	$ 1,374,180